What We Offer
What We Promise
At Atherotech, every research study is carefully planned and conducted to accommodate the needs and expectations of our clients and study sponsors. We work diligently to meet client needs and deadlines, never compromising clinical excellence or data integrity.
What We Offer
MANAGEMENT
- Rigorous internal quality assurance
- Standard and custom data management
- A variety of distribution options – website, data file, fax, mail and custom
- Qualified, competent research staff
- Timely, accurate results
- Information confidentiality
TESTING
- The VAP® Cholesterol Test
- hs-CRP
- Homocysteine
- Testing of Both Human and Animal Specimens
- Testing of Fresh or Frozen (-70F) Specimens
- Testing of Serum or Plasma Specimens
How Does the VAP Cholesterol Test Work?
The patented VAP Test is a single comprehensive test for all lipoprotein classes and subclasses, and consists of the following three sequential steps:
1) separation of lipoprotein classes and their subclasses according to their density, using vertical spin density gradient ultracentrifugation
2) continuous enzymatic cholesterol analysis of separated lipoproteins using the VAP analyzer
3) quantification of lipoprotein classes and subclasses in terms of their cholesterol concentration by deconvoluting the total cholesterol profile obtained in step 2, using proprietary software
Thus the VAP Test provides directly measured cholesterol concentrations of all major lipoprotein classes (HDL, LDL, VLDL, IDL, and Lp(a)) and their important subclasses, such as HDL2, HDL3, and LDL1 – LDL4. In addition, the VAP Test also provides LDL subclass pattern (A, A/B or B) and remnant lipoprotein cholesterol.
For more details, please refer to the following references or contact us at 800.719.9807.
Clin Lab Med 2006;26:787-802 and J Lipid Res 1994;35:159-168.
“Atherotech has been a welcome professional partner in our study of differences in outcomes following acute myocardial infarction. We believe that with Atherotech’s help, we can create fundamental insights into the link between fatty acids and patient recovery outcomes following AMI.”
- John A. Spertus, MD, MPH
Director, CV Education and Outcomes Research
Mid America Institute at Saint Luke’s Hospital
Professor, School of Medicine, University of Missouri-Kansas City
Research Studies
Our VAP technology has been chosen for the analysis of more than 65,000 clinical research specimens from a variety of studies, including those listed here:
- KALETRA Study
- Active Study
- Avandia Study
- BARC Study
- Emory Estrogen Vascular Study
- FORCE Trial
- Framingham Study
- FROST Study
- HATS Trial
- Johns Hopkins Sibling Study
- SHEAR Study
- Merck Safari and Silhouette Studies
- Early Trial
- Fibercel Pilot Trial
- NIA-NIH Vascular Aging Study
- Native American CHD Risk Factor Study
- AstraZeneca Rosuvastatin Study
- Pfizer-Lipitor Study
- Triumph Trial
- UPMC Heart SCORE Study
- Vanderbilt Pediatric Cardiovascular Morbidity Study
- RACED Study
- WAVE Trial
- Yale Pathophysiology of Type 2 Diabetes in Youth Study
“I found Atherotech to be an important asset to my research study. The company is highly professional and provided my online results in a timely and organized fashion.”
-Bonnie Marblestone, RN, CFNP, PhD-c,
Primary Investigator
University of San Diego School of Nursing
Who Is Using The VAP
Our Working Relationships
Atherotech has been involved in research testing for more than 100 clinical research studies and trials with institutions and organizations including:
- AstraZeneca
- AtheroGenics
- Ball State University
- Baylor College of Medicine
- Boston University School of Medicine
- Cincinnati Children’s Hospital
- Creighton University
- Duke University
- Emory School of Medicine
- Esoterix-LabCorp
- Genzyme Diagnostics
- GlaxoSmithKline
- International Institute for Biomedical Research
- Johns Hopkins
- Mayo Medical Laboratories
- Merck
- Merck Sharpe & Dohme
- Memorial Sloane-Kettering
- Metabasis
- Microbia
- National Institute of Health
- Oregon Research Institute
- Pfizer
- San Jose State University
- Stanford University
- Texas A&M University
- Texas Children’s Hospital
- The Medical College of Georgia
- The University of Alabama
- The University of Alabama at Birmingham
- The University of Calgary
- The University of California at San Diego
- The University of California at San Francisco
- The University of Colorado
- The University of Maryland
- The University of Minnesota Medical Center
- The University of Nevada at Reno
- The University of New Mexico
- The University of Pittsburgh
- The University of Rochester Medical Center
- The University of South Florida
- The University of Utah
- The University of Virginia
- The University of Washington
- Vanderbilt University
- Yale University School of Medicine
Our Research and Development Director
Kris Kulkarni, Ph.D., has been our director since 1999, specializing in testing cardiovascular risk markers. Prior to joining Atherotech, Dr. Kulkarni was with the Department of Medicine at the University of Alabama in Birmingham for 12 years. He began his career there as a postdoctoral fellow, rising to the position of Research Assistant Professor of Medicine. He was involved in every phase of the development of the VAP Test. Dr. Kulkarni is a member of the American Association of Clinical Chemistry (AACC) and has published extensively.
The VAP Test
Research &